跳转至内容
Merck
所有图片(1)

主要文件

G7798

Sigma-Aldrich

GYKI-53655 hydrate

>99.0% (HPLC)

别名:

1-(4-aminophenyl)-3-methylcarbamyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride, 5-(4-Aminophenyl)-8,9-dihydro-N,8-dimethyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide hydrochloride, LY300168 hydrochloride hydrate

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H20N4O3 · HCl · xH2O
分子量:
388.85 (anhydrous basis)
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

方案

>99.0% (HPLC)

表单

powder

颜色

yellow to orange

溶解性

H2O: >10 mg/mL

储存温度

2-8°C

SMILES字符串

[Cl-].N1(N=C(c3c(cc4c(c3)OCO4)CC1C)c2ccc(cc2)N)C(=O)NC.[H+]

InChI

1S/C19H20N4O3.ClH/c1-11-7-13-8-16-17(26-10-25-16)9-15(13)18(22-23(11)19(24)21-2)12-3-5-14(20)6-4-12;/h3-6,8-9,11H,7,10,20H2,1-2H3,(H,21,24);1H

InChI key

ASLCSBBDVWPSQT-UHFFFAOYSA-N

应用

GYKI-53655 hydrate has been used as a calcium-permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) receptor antagonist in single-particle tracking experiments.

生化/生理作用

GYKI-53655 also inhibits the kainate GluK3 homomeric and GluK2/3 heteromeric receptors. It exhibits anti-ischemic, anti-convulsant, and acute neuroprotective activity.
GYKI-53655 is an AMPA antagonist and noncompetitive negative allosteric modulator.

特点和优势

This compound is featured on the Glutamate Receptors (Ion Channel Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

象形图

Skull and crossbones

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 1

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

T Szabados et al.
Brain research bulletin, 55(3), 387-391 (2001-08-08)
GYKI 52466 [1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine], a non-competitive AMPA [alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate] and kainate receptor antagonist and its two analogues, GYKI 53405 [1-(4-aminophenyl)-3-acetyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine] and GYKI 53655 [1-(4-aminophenyl)-3-methylcarbamyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine] were investigated in two seizure models and in MgCl2 induced global cerebral ischaemia, as an acute neuroprotective model.
David Perrais et al.
Neuropharmacology, 56(1), 131-140 (2008-09-02)
A number of kainate receptor antagonists have shown selectivity for receptors containing the GluK1 subunit. Here, we analyze the effects of these GluK1 antagonists on currents mediated by recombinant homomeric GluK3 and heteromeric GluK2/3 receptors expressed in HEK 293 cells
Alice Polenghi et al.
Cell reports, 31(10), 107735-107735 (2020-06-11)
Kainate receptors (KARs) mediate postsynaptic currents with a key impact on neuronal excitability. However, the molecular determinants controlling KAR postsynaptic localization and stabilization are poorly understood. Here, we exploit optogenetic and single-particle tracking approaches to study the role of KAR

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持